- Home
- CTM vs OTLK Comparison
CTM vs OTLK Comparison
Compare CTM & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTM
- OTLK
- Stock Information
- Founded
- CTM 2019
- OTLK 2010
- Country
- CTM United States
- OTLK United States
- Employees
- CTM N/A
- OTLK N/A
- Industry
- CTM EDP Services
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CTM Technology
- OTLK Health Care
- Exchange
- CTM Nasdaq
- OTLK Nasdaq
- Market Cap
- CTM 54.7M
- OTLK 56.3M
- IPO Year
- CTM N/A
- OTLK 2016
- Fundamental
- Price
- CTM $1.11
- OTLK $1.48
- Analyst Decision
- CTM
- OTLK Strong Buy
- Analyst Count
- CTM 0
- OTLK 5
- Target Price
- CTM N/A
- OTLK $10.20
- AVG Volume (30 Days)
- CTM 6.4M
- OTLK 467.0K
- Earning Date
- CTM 03-24-2025
- OTLK 02-14-2025
- Dividend Yield
- CTM N/A
- OTLK N/A
- EPS Growth
- CTM N/A
- OTLK N/A
- EPS
- CTM N/A
- OTLK N/A
- Revenue
- CTM $44,764,852.00
- OTLK N/A
- Revenue This Year
- CTM $29.25
- OTLK N/A
- Revenue Next Year
- CTM N/A
- OTLK $288.46
- P/E Ratio
- CTM N/A
- OTLK N/A
- Revenue Growth
- CTM 3.12
- OTLK N/A
- 52 Week Low
- CTM $0.12
- OTLK $0.87
- 52 Week High
- CTM $2.83
- OTLK $12.85
- Technical
- Relative Strength Index (RSI)
- CTM 51.11
- OTLK 41.52
- Support Level
- CTM $1.02
- OTLK $1.38
- Resistance Level
- CTM $1.30
- OTLK $1.56
- Average True Range (ATR)
- CTM 0.21
- OTLK 0.12
- MACD
- CTM -0.00
- OTLK 0.02
- Stochastic Oscillator
- CTM 39.13
- OTLK 59.26
About CTM Castellum Inc.
Castellum Inc is engaged in providing information technology services. The company provides financial services, healthcare, and other users of large data applications with services that include intelligence analysis, software development, software engineering, program management, strategic and mission planning, information assurance, cybersecurity and policy support, data analytics, and MBSE. In addition to constantly innovating and enhancing organic capabilities, Castellum is acquiring technology companies in the areas of cybersecurity, information technology, electronic warfare, information warfare, and information operations with businesses in the defense, federal, civilian, and commercial markets.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.